Compare ATEC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | EYPT |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2006 | 2005 |
| Metric | ATEC | EYPT |
|---|---|---|
| Price | $9.30 | $4.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $22.00 | ★ $31.80 |
| AVG Volume (30 Days) | 2.3M | ★ 5.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.04 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $101,739,000.00 | $7,539,000.00 |
| Revenue This Year | $18.97 | N/A |
| Revenue Next Year | $16.70 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.82 | $3.95 |
| 52 Week High | $23.29 | $19.11 |
| Indicator | ATEC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 29.08 |
| Support Level | $8.90 | $3.95 |
| Resistance Level | $9.75 | $15.17 |
| Average True Range (ATR) | 0.44 | 0.85 |
| MACD | -0.05 | -0.82 |
| Stochastic Oscillator | 36.25 | 10.13 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.